CEO: Aratana is focused on 'near-term value enhancement,' but R&D will continue
March 13, 2019 at 12:07 PM EDT
Craig Tooman, the new CEO of Aratana Therapeutics Inc., said that the company is focused on "near-term value enhancement," but that a promising new drug will be a focus of R&D expenses in 2019.
